GPT Healthcare Limited , a prominent healthcare provider in Eastern India, has reported a 9.8% year-on-year increase in total income for the first half of fiscal year 2026 (H1FY26). The company's financial results, released on November 8, 2025, showcase both growth and challenges in the healthcare sector.

Financial Highlights

• Total income rose to Rs 228.92 crore in H1FY26, up from Rs 208.50 crore in H1FY25.
• Revenue from operations grew by 11% to Rs 226.00 crore.
• EBITDA margin compressed to 18.8% from 22.2% in the previous year.
• Net profit declined by 26.2% to Rs 18.30 crore, compared to Rs 24.70 crore in H1FY25.

Operational Performance

GPT Healthcare operates a network of five multispecialty hospitals across Eastern India, with a total capacity of 719 beds. Key operational metrics for H1FY26 include:

Expansion and Strategic Initiatives

The company has been actively pursuing growth opportunities:

• A new 158-bed hospital was commissioned in Raipur in May 2025.
• GPT Healthcare aims to become a 1,000-bed facility within the next two years.
• The expansion strategy focuses on Tier I and Tier II cities in Eastern India.

Dividend Declaration

The Board of Directors has declared an interim dividend of Re 1 per share for the financial year 2025-26. The record date for dividend eligibility is set for November 14, 2025, with payment expected on or before December 7, 2025.

Management Changes

In a significant leadership transition, the Board has approved the following appointments:

• Dr. Om Tantia has been elevated to the position of Chairman and Managing Director.
• Mr. Shree Gopal Tantia has been appointed as Vice Chairman of the company.

Both appointments are effective from November 8, 2025.

Financial Position

As of September 30, 2025, GPT Healthcare's balance sheet reflects:

• Total assets of Rs 463.50 crore
• Total equity of Rs 253.80 crore
• Current ratio of approximately 1.03

Outlook

While GPT Healthcare has demonstrated revenue growth, the decline in profitability and EBITDA margin suggests challenges in cost management and operational efficiency. The company's expansion plans and strategic focus on Eastern India's underserved markets may provide opportunities for future growth, but careful execution will be crucial in improving financial performance.

Investors and stakeholders will likely monitor how the new leadership navigates these challenges and capitalizes on the company's expansion strategy in the coming quarters.

GPT Healthcare Limited , a prominent player in the healthcare sector, has announced its financial results for the second quarter, along with an interim dividend declaration. The company's performance shows a mixed picture, with revenue growth but a decline in profitability.

Financial Performance

GPT Healthcare reported a decrease in net profit for Q2, while simultaneously achieving an increase in revenue. Here's a breakdown of the key financial metrics:

The company's revenue showed a notable increase of 13.33% year-over-year, rising from ₹1.05 billion to ₹1.19 billion. However, this top-line growth did not translate into higher profitability. Net profit declined by 28.38%, from ₹148.00 million in the previous year to ₹106.00 million in the current quarter.

EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) also saw a slight decrease, falling from ₹234.20 million to ₹227.40 million. Consequently, the EBITDA margin contracted from 22.17% to 19.13%, indicating some pressure on operational efficiency.

Dividend Declaration

GPT Healthcare's Board of Directors has recommended an interim dividend of ₹1 per share. This represents a 10% dividend on the face value of the equity shares, which stand at ₹10 each.

Key details of the dividend declaration include:

• Dividend Rate: 10% (₹1 per share)
• Record Date: November 14, 2025
• Expected Payment Date: On or before December 7, 2025

Management Changes

The company also announced significant changes in its leadership structure:

1. Dr. Om Tantia, previously the Managing Director, has been elevated to the position of Chairman and Managing Director, effective November 8, 2025.
2. Mr. Shree Gopal Tantia, formerly a Non-Executive Director, has been appointed as the Vice Chairman of the company, also effective from November 8, 2025.

These management changes suggest a strategic realignment at the top level, which could influence the company's future direction and operations.

GPT Healthcare's mixed Q2 results, coupled with the dividend announcement and management restructuring, present a complex picture for investors and stakeholders. While the revenue growth is encouraging, the decline in profitability may warrant closer attention to the company's cost management and operational strategies in the coming quarters.